29 analysts have expressed a variety of opinions on Biomarin Pharmaceutical BMRN over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 13 | 10 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 3 | 4 | 0 | 0 |
| 2M Ago | 3 | 4 | 3 | 0 | 0 |
| 3M Ago | 2 | 5 | 3 | 0 | 0 |
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $96.03, a high estimate of $122.00, and a low estimate of $65.00. A decline of 8.09% from the prior average price target is evident in the current average.
Investigating Analyst Ratings: An Elaborate Study
The perception of Biomarin Pharmaceutical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Akash Tewari | Wolfe Research | Announces | Outperform | $95.00 | - |
| David Lebovitz | Citigroup | Lowers | Neutral | $81.00 | $93.00 |
| Whitney Ijem | Canaccord Genuity | Lowers | Hold | $84.00 | $93.00 |
| Olivia Brayer | Cantor Fitzgerald | Lowers | Overweight | $90.00 | $110.00 |
| Jessica Fye | JP Morgan | Lowers | Overweight | $109.00 | $110.00 |
| Luca Issi | RBC Capital | Maintains | Sector Perform | $80.00 | $80.00 |
| Cory Kasimov | Evercore ISI Group | Lowers | Outperform | $105.00 | $115.00 |
| Eliana Merle | UBS | Raises | Buy | $106.00 | $104.00 |
| Joel Beatty | Baird | Lowers | Neutral | $65.00 | $72.00 |
| Danielle Brill | Raymond James | Announces | Outperform | $79.00 | - |
| Luca Issi | RBC Capital | Lowers | Sector Perform | $80.00 | $85.00 |
| Gena Wang | Barclays | Lowers | Overweight | $86.00 | $110.00 |
| George Farmer | Scotiabank | Lowers | Sector Perform | $78.00 | $95.00 |
| Joon Lee | Truist Securities | Lowers | Buy | $90.00 | $118.00 |
| Mohit Bansal | Wells Fargo | Lowers | Overweight | $90.00 | $115.00 |
| Luca Issi | RBC Capital | Lowers | Sector Perform | $85.00 | $100.00 |
| Geoff Meacham | B of A Securities | Lowers | Buy | $115.00 | $130.00 |
| Paul Matteis | Stifel | Lowers | Buy | $87.00 | $115.00 |
| William Pickering | Bernstein | Lowers | Outperform | $90.00 | $116.00 |
| Whitney Ijem | Canaccord Genuity | Maintains | Hold | $93.00 | $93.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $110.00 | $110.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $120.00 | $111.00 |
| Luca Issi | RBC Capital | Maintains | Sector Perform | $100.00 | $100.00 |
| George Farmer | Scotiabank | Raises | Sector Perform | $95.00 | $86.00 |
| Joon Lee | Truist Securities | Lowers | Buy | $118.00 | $140.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $122.00 | $107.00 |
| Christopher Raymond | Piper Sandler | Maintains | Overweight | $107.00 | $107.00 |
| Paul Matteis | Stifel | Raises | Buy | $115.00 | $112.00 |
| William Pickering | Bernstein | Raises | Outperform | $110.00 | $94.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biomarin Pharmaceutical. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Biomarin Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Biomarin Pharmaceutical analyst ratings.
Unveiling the Story Behind Biomarin Pharmaceutical
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Biomarin Pharmaceutical: Delving into Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Biomarin Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.28% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of 14.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE excels beyond industry benchmarks, reaching 1.98%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Biomarin Pharmaceutical's ROA excels beyond industry benchmarks, reaching 1.52%. This signifies efficient management of assets and strong financial health.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
